Diffuse Hemispheric Glioma, H3 G34-Mutant
specificA WHO grade 4 diffuse glioma arising in the cerebral hemispheres. It is characterized by the presence of missense mutation of the H3-3A gene. The prognosis is poor.
9
Centers
9
Active Trials
—
Cancer Funding
Top Centers for Diffuse Hemispheric Glioma, H3 G34-Mutant(9)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive Active Research Program | 55.6 |
| 2 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive Active Research Program | 55.6 |
| 3 | Duke Cancer InstituteDurham, NC NCI Comprehensive Active Research Program | 55.6 |
| 4 | University of Colorado Cancer CenterAurora, CO NCI Comprehensive Active Research Program | 55.6 |
| 5 | Holden Comprehensive Cancer CenterIowa City, IA NCI Comprehensive Active Research Program | 55.6 |
| 6 | University of Illinois Cancer CenterChicago, IL Active Research Program | 55.6 |
| 7 | Boston University Cancer CenterBoston, MA Active Research Program | 55.6 |
| 8 | Cancer Center at IllinoisUrbana, IL Active Research Program | 55.6 |
| 9 | University of Cincinnati Cancer CenterCincinnati, OH Active Research Program | 55.6 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →